Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Cambrian launches new subsidiary to develop mTOR inhibitors

Novartis deal gives Tornado Therapeutics assets for age-related diseases

By Stephen Hansen, Associate Editor
February 17, 2022 12:32 AM UTC

Cambrian has added to its age-related disease portfolio via a deal with Novartis for a series of mTOR inhibitors that will be developed by newly launched subsidiary Tornado Therapeutics.

Cambrian Biopharma Inc. acquired exclusive, worldwide rights to a group of selective mTOR inhibitors from Novartis AG (NYSE:NVS; SIX:NOVN) for an undisclosed upfront payment. Novartis is also eligible for undisclosed milestones, plus royalties. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Novartis AG